MRKS-Brand-Logo-Final-FullColor.png
Merakris Therapeutics Announces FDA Clearance for Part 2 of its Phase II Multicenter Investigational New Drug Study of Dermacyte® Liquid
05 sept. 2024 06h30 HE | Merakris Therapeutics
Part 2 of the Phase II multicenter clinical study for the investigational wound care drug, Dermacyte® Amniotic Wound Care Liquid, will begin late 2024.
merakris_logo_4color copy.jpg
Merakris To Share Data from Fully Enrolled First Part of Two-Part Dermacyte® Liquid Clinical Trial
05 déc. 2023 06h30 HE | Merakris Therapeutics
Merakris Therapeutics announces it has fully enrolled the first part of a clinical trial to evaluate its investigational drug product, Dermacyte® Liquid.
merakris_logo_4color copy.jpg
Wound Healing Technology Company Merakris Adds Two Executives to Leadership Team
15 août 2023 06h30 HE | Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Merakris Therapeutics has added two new executives to its leadership team as it prepares to expand its product line and increase its...
Global Toxoplasmosis Testing Market Aims for US$ 3.5 billion by 2033, Enhancing Diagnostic Precision: Persistence Market Research
09 août 2023 12h25 HE | Persistence Market Research
New York, Aug. 09, 2023 (GLOBE NEWSWIRE) -- The global toxoplasmosis testing market recorded a valuation of US$ 1.9 billion in 2022 and is forecasted to expand at a CAGR of 5.8% from 2023 to 2033,...
merakris_logo_4color copy.jpg
Study Shows Effectiveness of Merakris’ Wound Care Products
02 juin 2022 07h30 HE | Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., June 02, 2022 (GLOBE NEWSWIRE) -- A peer-reviewed case study in the May 21 edition of SAGE Open Medical Case Reports highlights the effectiveness of two Merakris...
Merakris Therapeutics, Inc. Announces FDA Clearance for Dermacyte® Liquid Clinical Trial
25 mai 2021 09h00 HE | Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Merakris Therapeutics, Inc. (Merakris) announced that it has received U.S. Food and Drug Administration (FDA) clearance for a Phase II...
AmnioLife to Partici
AmnioLife to Participate at First Annual Interventional Orthopedic Foundation Conference October 23rd & 24th
06 oct. 2015 05h00 HE | AmnioLife Corporation
GAINESVILLE, Fla., Oct. 06, 2015 (GLOBE NEWSWIRE) -- AmnioLife Corporation, a human cells, tissues, and cellular and tissue-based products developer, today announced that its CEO and Lead Scientist...